MetaCap

Bicycle Therapeutics (BCYC) vs Yarrow Bioscience (YARW)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Yarrow Bioscience (YARW) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 26.7% versus a loss of 54.1%. Over five years, BCYC leads with a -94.7% price change compared with -98.6% for YARW. Bicycle Therapeutics is the larger company by market cap ($203.3 million vs $196.5 million), about 1.0 times the size.

Bicycle Therapeutics converts more of its revenue into profit, with a net margin of -301.7% versus -4646.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCYC-54.11%YARW-26.70%
+173%+54%-65%
Nov 21, 20251 yearNov 20, 2026
BCYC-95.01%YARW-98.66%
+47%-29%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCYC versus YARW key metrics
MetricBCYCYARW
Share price$2.90$12.90
Market cap$203.27M$196.53M
1-day change-4.92%-9.35%
YTD return-59.04%-55.52%
1-year return-54.11%-26.70%
5-year return-94.69%-98.61%
EPS (TTM)$-2.03—
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.59M$570.00K
Revenue growth (YoY)+105.77%+13.77%
Net income (latest FY)$-218.96M$-26.48M
Operating margin-340.38%-5219.12%
Net margin-301.66%-4646.14%
52-week high$7.83$46.95
52-week low$2.85$12.39
Distance from 52-week high-62.96%-72.52%
Analyst consensusbuystrong_buy
Avg. price target upside+216.21%+310.85%
Average volume444.72K153.34K
Shares outstanding50.66M15.23M
Employees2887
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • YARW has outperformed BCYC by 27.4 percentage points over the past year.
  • Bicycle Therapeutics is more profitable, keeping -301.7 cents of every revenue dollar as net income versus -4646.1 cents for Yarrow Bioscience.
  • Bicycle Therapeutics grew revenue faster in its latest fiscal year (+105.77% vs +13.77%).

About Bicycle Therapeutics

BCYC stock →

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.

Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees

About Yarrow Bioscience

YARW stock →

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

BCYC vs YARW FAQ

Which is bigger, Bicycle Therapeutics or Yarrow Bioscience?

Bicycle Therapeutics (BCYC) is larger, with a market capitalization of $203.27M compared with $196.53M for Yarrow Bioscience (YARW).

Which stock has performed better over the past year, BCYC or YARW?

YARW returned -26.70% over the past 12 months, compared with -54.11% for BCYC (price return, excluding dividends). Past performance does not predict future results.

Are Bicycle Therapeutics and Yarrow Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons